Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.58 CAD -0.6%
Market Cap: 134.3m CAD
Have any thoughts about
Biosyent Inc?
Write Note

Intrinsic Value

The intrinsic value of one RX stock under the Base Case scenario is 9.84 CAD. Compared to the current market price of 11.58 CAD, Biosyent Inc is Overvalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RX Intrinsic Value
9.84 CAD
Overvaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Biosyent Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
RX
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for RX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about RX?
Bearish
Neutral
Bullish

Fundamental Analysis

11.58 CAD
-0.6%
-0.6%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Biosyent Inc
CA
Pharmaceuticals
Market Cap
134.3m CAD
IPO
May 22, 1981
Employees
-
Canada
Market Cap
134.3m CAD
Industry
Pharmaceuticals
IPO
May 22, 1981
Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Biosyent Inc

Provide an overview of the primary business activities
of Biosyent Inc.

What unique competitive advantages
does Biosyent Inc hold over its rivals?

What risks and challenges
does Biosyent Inc face in the near future?

Summarize the latest earnings call
of Biosyent Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biosyent Inc.

Provide P/S
for Biosyent Inc.

Provide P/E
for Biosyent Inc.

Provide P/OCF
for Biosyent Inc.

Provide P/FCFE
for Biosyent Inc.

Provide P/B
for Biosyent Inc.

Provide EV/S
for Biosyent Inc.

Provide EV/GP
for Biosyent Inc.

Provide EV/EBITDA
for Biosyent Inc.

Provide EV/EBIT
for Biosyent Inc.

Provide EV/OCF
for Biosyent Inc.

Provide EV/FCFF
for Biosyent Inc.

Provide EV/IC
for Biosyent Inc.

Show me price targets
for Biosyent Inc made by professional analysts.

What are the Revenue projections
for Biosyent Inc?

How accurate were the past Revenue estimates
for Biosyent Inc?

What are the Net Income projections
for Biosyent Inc?

How accurate were the past Net Income estimates
for Biosyent Inc?

What are the EPS projections
for Biosyent Inc?

How accurate were the past EPS estimates
for Biosyent Inc?

What are the EBIT projections
for Biosyent Inc?

How accurate were the past EBIT estimates
for Biosyent Inc?

Compare the revenue forecasts
for Biosyent Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biosyent Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biosyent Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biosyent Inc compared to its peers.

Compare the P/E ratios
of Biosyent Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Biosyent Inc with its peers.

Analyze the financial leverage
of Biosyent Inc compared to its main competitors.

Show all profitability ratios
for Biosyent Inc.

Provide ROE
for Biosyent Inc.

Provide ROA
for Biosyent Inc.

Provide ROIC
for Biosyent Inc.

Provide ROCE
for Biosyent Inc.

Provide Gross Margin
for Biosyent Inc.

Provide Operating Margin
for Biosyent Inc.

Provide Net Margin
for Biosyent Inc.

Provide FCF Margin
for Biosyent Inc.

Show all solvency ratios
for Biosyent Inc.

Provide D/E Ratio
for Biosyent Inc.

Provide D/A Ratio
for Biosyent Inc.

Provide Interest Coverage Ratio
for Biosyent Inc.

Provide Altman Z-Score Ratio
for Biosyent Inc.

Provide Quick Ratio
for Biosyent Inc.

Provide Current Ratio
for Biosyent Inc.

Provide Cash Ratio
for Biosyent Inc.

What is the historical Revenue growth
over the last 5 years for Biosyent Inc?

What is the historical Net Income growth
over the last 5 years for Biosyent Inc?

What is the current Free Cash Flow
of Biosyent Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biosyent Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biosyent Inc

Current Assets 27.6m
Cash & Short-Term Investments 17.1m
Receivables 4.4m
Other Current Assets 6.1m
Non-Current Assets 17.9m
Long-Term Investments 10.5m
PP&E 1.3m
Intangibles 5.7m
Other Non-Current Assets 458.2k
Current Liabilities 7m
Accounts Payable 6.3m
Other Current Liabilities 783k
Non-Current Liabilities 1.1m
Long-Term Debt 892.9k
Other Non-Current Liabilities 197.3k
Efficiency

Earnings Waterfall
Biosyent Inc

Revenue
34.5m CAD
Cost of Revenue
-7.1m CAD
Gross Profit
27.4m CAD
Operating Expenses
-19.2m CAD
Operating Income
8.2m CAD
Other Expenses
-1.1m CAD
Net Income
7.1m CAD

Free Cash Flow Analysis
Biosyent Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RX Profitability Score
Profitability Due Diligence

Biosyent Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Gross Profit
Positive Free Cash Flow
Exceptional ROIC
71/100
Profitability
Score

Biosyent Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

RX Solvency Score
Solvency Due Diligence

Biosyent Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Long-Term Solvency
Negative Net Debt
99/100
Solvency
Score

Biosyent Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RX Price Targets Summary
Biosyent Inc

Wall Street analysts forecast RX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RX is 11.99 CAD with a low forecast of 11.87 CAD and a high forecast of 12.34 CAD.

Lowest
Price Target
11.87 CAD
2% Upside
Average
Price Target
11.99 CAD
3% Upside
Highest
Price Target
12.34 CAD
7% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RX?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for RX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one RX stock?

The intrinsic value of one RX stock under the Base Case scenario is 9.84 CAD.

Is RX stock undervalued or overvalued?

Compared to the current market price of 11.58 CAD, Biosyent Inc is Overvalued by 15%.

Back to Top